作者: Victoria M. Richon , Judy H. Chiao , Thomas A. Miller , William Kevin Kelly
DOI:
关键词: Non-Hodgkin's lymphoma 、 In vivo 、 Pharmacology 、 Biology 、 Bioavailability 、 Hodgkin s 、 Histone deacetylase 、 Dosing regimen 、 Cell growth 、 Apoptosis
摘要: The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis neoplastic cells, inhibiting histone deacetylase (HDAC) by administration pharmaceutical compositions comprising potent HDAC inhibitors. oral bioavailability the active compounds in is surprisingly high. Moreover, unexpectedly give rise to high, therapeutically effective blood levels over an extended period time. further a safe, daily dosing regimen these compositions, which easy follow, and results amount inhibitors vivo.